NCT04133506View on ClinicalTrials.gov

PGE2/IL-22 Pathway in Various Forms of Eczema

Active, not recruitingOBSERVATIONAL

Enrollment

60

Participants

Timeline

Start Date

November 4, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Eczema

Interventions

DRUG

Aspirin 300mg

see earlier (only half of healthy volunteers receive aspirin)

Trial Locations (1)

Unknown

QMRI, Edinburgh

All Listed Sponsors

lead

NHS Lothian

OTHER_GOV